Karo Bio AB is finalizing the design of a Phase III program for its lead drug candidate, eprotirome (KB2115), which is in development for heterozygous familial hypercholesterolemia (HeFH), a genetic condition characterized by the accumulation of elevated levels of low density lipoprotein (LDL) cholesterol and increased risk of atherosclerosis at an early age. (BioWorld International) Read More